

# The Role of Diagnostic Ability in Markets for Expert Services

Fang Liu, Alexander Rasch, Marco A. Schwarz, Christian Waibel



### Impressum:

CESifo Working Papers ISSN 2364-1428 (electronic version) Publisher and distributor: Munich Society for the Promotion of Economic Research - CESifo GmbH The international platform of Ludwigs-Maximilians University's Center for Economic Studies and the ifo Institute Poschingerstr. 5, 81679 Munich, Germany Telephone +49 (0)89 2180-2740, Telefax +49 (0)89 2180-17845, email office@cesifo.de Editor: Clemens Fuest https://www.cesifo.org/en/wp An electronic version of the paper may be downloaded • from the SSRN website: www.SSRN.com

- from the RePEc website: <u>www.RePEc.org</u>
- from the CESifo website: <u>https://www.cesifo.org/en/wp</u>

# The Role of Diagnostic Ability in Markets for Expert Services

# Abstract

In credence goods markets, experts have better information about the appropriate quality of treatment than their customers. Experts may exploit their informational advantage by defrauding customers. Market institutions have been shown theoretically to be effective in mitigating fraudulent expert behavior. We analyze whether this positive result carries over to a situation in which experts are heterogeneous in their diagnostic abilities. We find that efficient market outcomes are always possible. However, inefficient equilibria can also exist. If, in equilibrium, experts provide diagnosis-independent treatments, an increase in experts' ability or in the probability of high-ability experts might not improve relative market efficiency.

JEL-Codes: D820, L150.

Keywords: credence good, diagnosis, expert, fraud, overtreatment, undertreatment.

Fang Liu University of Duesseldorf / DICE Germany – 40225 Duesseldorf liu@dice.hhu.de

Marco A. Schwarz Department of Economics University of Innsbruck / Austria marco.schwarz@uibk.ac.at Alexander Rasch\* University of Duesseldorf / DICE Germany – 40225 Duesseldorf rasch@dice.hhu.de

Christian Waibel Center of Economic Research ETH Zurich / Switzerland cwaibel@ethz.ch

\*corresponding author

November 12, 2020

We thank Winand Emons, Johannes Johnen, Rudolf Kerschbamer, Qianshuo Liu, Anastasia Parakhonyak, and Giuseppe Pignataro for very helpful comments and discussions. The authors are grateful for comments by participants at the economics seminars in Innsbruck, Paderborn, Brno (Masaryk University), Frankfurt (Goethe University and Frankfurt School), Mannheim (ZEW), and Washington, D.C. (Howard University), the 17th International Industrial Organization Conference (Boston), the NOeG Annual Meeting (Graz), the Midwest Economic Theory and International Trade Conference (Bloomington), the 2019 Asia Meeting of the Econometric Society (Xiamen), the 2019 Econometric Society Australasian Meeting (Perth), the 2019 EARIE (Barcelona), the 2019 JEI (Madrid), and the ASSET 2019 Conference (Athens). Financial support by the Austrian Science Fund (SFB F63), the Fritz Thyssen Foundation and the Deutsche Forschungsgemeinschaft (DFG, project no. 235577387/GRK1974) is gratefully acknowledged.

# 1 Introduction

There is plenty of evidence that in markets for expert services (e.g., medical treatments, repairs, and financial and legal advice), diagnostic abilities differ across experts, and that these abilities are far from perfect. For example, Chan et al. (2019) show that skill plays an important role in pneumonia diagnoses by U.S. radiologists; Xue et al. (2019) show in their quasi-experimental study that lack of sufficient diagnostic knowledge is an important driver of the large amount of inappropriate antibiotic prescription in rural China; and the ECDC Technical Report (2019) finds that "uncertain diagnosis" was a common reason for antibiotic prescribing in cases in which prescribers (mostly medical doctors in EU/EEA countries) would have preferred not to prescribe (26% stated this as a reason occurring at least once during the previous week).<sup>1</sup>

However, the theoretical literature following Dulleck and Kerschbamer (2006) generally assumes that experts can perfectly diagnose their customers' problems, and sometimes makes predictions that do not seem to be in line with real-world observations. For example, Dulleck and Kerschbamer (2006) highlight that fraudulent behavior does not occur, and experts serve customers efficiently when customers are ex-ante homogeneous, when they are committed to undergoing treatment after receiving a diagnosis, and when either the treatment is verifiable, or experts are liable; yet, inadequate treatments are an important issue in real-life credence goods markets.<sup>2</sup>

We theoretically analyze whether and how experts' diagnostic abilities change the market outcome in a credence goods market. Our model captures two types of scenarios that represent a wide range of important real-life credence goods markets. First, our set-up applies to those markets in which customers require immediate care and in which experts must rely on talent, experience, and/or specific knowledge (for example, mathematical skills), which cannot be acquired or extended in the short or medium term.<sup>5</sup> Such a limitation to invest

 $^{5}$ Brush et al. (2017) provide an overview of research that analyzes diagnostic decisionmaking by expert clinicians. The authors highlight the importance of expertise and expe-

 $<sup>^{1}\</sup>mathrm{Further}$  examples include Lambert and Wertheimer (1988), Brammer (2002), and Coderre et al. (2009).

<sup>&</sup>lt;sup>2</sup>In the U.S. healthcare market, for example, the FBI estimates that up to 10% of the 3.3 trillion US\$ of yearly health expenditures are due to fraud (Federal Bureau of Investigation, 2011).<sup>3</sup> Gottschalk et al. (2018) show that 28% of dentists' treatment recommendations involve overtreatment recommendations. In car repair services, Taylor (1995), Schneider (2012), and Rasch and Waibel (2018) report fraud performed by garages. Fraud in computer repair services has been documented by Kerschbamer et al. (2016). Balafoutas et al. (2013) and Balafoutas et al. (2017) document fraud in the market for taxi rides. Moreover, fraudulent behavior has been reported in several lab experiments on credence goods (see, e.g., Dulleck et al., 2011; Mimra et al., 2016a,b).<sup>4</sup>

in skills may also be due to capacity or time constraints. Second, as we show in an extension, our results extend to many situations in which experts exert unobservable effort to increase their diagnostic ability, or in which such effort is observable, but experts are homogeneous with regard to the effort costs involved. Importantly, we assume that prices are not completely fixed, and they are at least partially borne by customers, as is the case for most repair services and many dental and some medical treatments in numerous countries.

Our model bases on the standard credence goods model by Dulleck and Kerschbamer (2006).<sup>6</sup> A credence good is a good for which customers do not know which type of quality they need. By contrast, experts learn the necessary quality after performing a diagnosis. Because experts often perform both the diagnosis and the treatment, experts may exploit their informational advantage in one of three different ways. First, when experts overtreat customers, they provide more expensive treatments than necessary. Second, when experts undertreat their customers, they provide an insufficient treatment. Third, when experts overcharge their customers, they charge for more expensive treatments than provided. In this paper, we focus on the first two forms of fraud and the inefficiencies caused by such a behavior. In our set-up, (inefficient) overtreatment and/or undertreatment can occur due to the heterogeneity in experts' diagnostic abilities. Experts can have low or high diagnostic ability, but customers do not observe the type of experts with whom they interact. We are interested in how such differences in diagnostic quality affects expert behavior and market efficiency, and whether better diagnostic abilities yield more efficient outcomes. In contrast to earlier contributions (see the literature overview below) and motivated by the above-mentioned circumstances in many credence goods markets, our basic model assumes that diagnosis outcomes are exogenous, that is, more effort or higher investments do not affect diagnostic quality. This has important welfare implications, because always recommending the major or minor treatment can be socially optimal in this case.

Our results can be summarized as follows. As a benchmark, we analyze the situation in which expert types are known. In this case, we find that a low-ability expert who performs a correct diagnosis only with some probability – just like a high-ability expert who always correctly identifies a customer's major or minor problem – efficiently serves the market. In contrast to a high-ability expert type, however, such efficient behavior can require to always perform the major or minor treatment. With unobservable types, multiple pooling equilibria ex-

rience when they conclude that "[t]he ability to rapidly access experiential knowledge is a hallmark of expertise. Knowledge-oriented interventions [...] may improve diagnostic accuracy, but there is no substitute for experience gained through broad clinical exposure" (pp. 632–633).

<sup>&</sup>lt;sup>6</sup>The seminal article on credence goods markets is by Darby and Karni (1973).

ist. There always exists an efficient equilibrium. Depending on the diagnostic ability and the probability for a high-ability expert type, inefficient equilibria can also exist. An inefficient equilibrium is characterized by the low-ability expert type relying on the diagnosis too often, by both types always providing the major treatment, or by both types always providing the minor treatment. When expert types coordinate on the inefficient equilibria, a higher probability for a high-ability expert type can aggravate relative market inefficiencies. The intuition is as follows: Assume expert types coordinate on an equilibrium in which both expert types always provide the major treatment. Then, increasing the probability for a high-ability expert type would improve the market outcome in the efficient equilibria, because more correct diagnoses are performed. However, in contrast to these efficient equilibria, a high-ability expert type sticks to always providing a major treatment in the inefficient equilibria. A similar reasoning applies to a marginal improvement in the low-ability's diagnostic ability. When the expert types and the customers coordinate on an equilibrium in which both types exclusively provide the major treatment, the improvement in diagnostic ability does not lead to a better market outcome. We also show that our results are robust to certain forms of diagnosis effort and to competition. Moreover, we find that warranties or fines are effective policy tools when the success or the failure of a treatment is verifiable.

Previous literature offers evidence that the efficiency benchmark result with homogeneous experts and customers and liability or verifiability breaks down when heterogeneity is introduced.<sup>7</sup> Dulleck and Kerschbamer (2009) investigate credence goods markets with heterogeneous experts in a retail environment.<sup>8</sup> Customers need a costly diagnosis to find out which service they need. High-ability experts ("specialized dealers") can provide a diagnosis, whereas low-ability experts ("discounters") cannot. High-ability experts can provide both minor and major services. By contrast, low-ability experts can only provide the minor service.<sup>9</sup> In a dynamic set-up in which customers can visit multiple experts, the incentive for experts to provide a diagnosis diminishes if customers' switching costs are sufficiently low.<sup>10</sup>

<sup>&</sup>lt;sup>7</sup>Emons (1997, 2001) does not rely on heterogeneity, but shows that if a monopolist expert's capacities are not fully utilized, the expert fills these unused capacities by overtreatment. Gottschalk et al. (2018) provide experimental evidence.

<sup>&</sup>lt;sup>8</sup>Fong (2005), Dulleck and Kerschbamer (2006), Hyndman and Ozerturk (2011), and Jost et al. (2019) study customer heterogeneity in credence goods markets.

<sup>&</sup>lt;sup>9</sup>Alger and Salanié (2006) and Obradovits and Plaickner (2020) also look at settings with (observable) high-ability experts and discounters, but they only consider the case in which the high type's diagnostic ability is exogenously perfect.

 $<sup>^{10}</sup>$ By contrast, Bester and Dahm (2017) build on Dulleck and Kerschbamer (2009) and allow for an additional service in the second period in case the service in period one turns out to be insufficient, where the delay in service is costly. The authors show that if the delay

Frankel and Schwarz (2014) also employ a dynamic set-up, to study experts heterogeneous with respect to their costs. Customers return to an expert who provides the minor treatment and visit another expert with positive probability if they receive a major treatment if costs are observable. If experts' costs are not observable for customers, the first best cannot be implemented. Relatedly, Hilger (2016) extends Dulleck and Kerschbamer (2006)'s model by assuming heterogeneity in experts' treatment costs. Treatment costs are no longer observable to customers. Hence, experts cannot credibly signal to provide the appropriate treatment anymore.<sup>11</sup> Then, experts can take advantage of their expert status, resulting in equilibrium mistreatment in a wide range of price-setting and market environments.<sup>12</sup>

Moreover, Kerschbamer et al. (2017) find theoretical and experimental evidence that inefficient market outcomes with fraud can arise due to the heterogeneity in experts' social preferences. In particular, experts displaying a strong inequity aversion are reported to overtreat or undertreat customers to reduce differences in payoffs.

The article closest to ours is Schneider and Bizer (2017a), who offer an extension of the setup in Pesendorfer and Wolinsky (2003).<sup>13</sup> Whereas Pesendorfer and Wolinsky (2003) assume that experts are homogeneous and must decide whether they exert high or low diagnosis effort, Schneider and Bizer (2017a) consider two types of experts. Again, both types must decide whether to exert high or low diagnosis effort, and both types perform an accurate diagnosis when they choose high effort. However, experts differ when they decide to only exert low effort: In this case, the low-ability expert type always misdiagnoses a customer's problem, which is drawn from a continuum of problems, but the high-ability expert type recommends the accurate treatment with some probability. In contrast to the present setup, customers can search for multiple opinions. The authors find that with a sufficient number of high-ability experts, there is the possibility for a second-best equilibrium in which welfare is maximized even without a policy intervention of fixing prices. Moreover, in line with Pesendorfer and Wolinsky (2003), given a small share of high-ability experts, a second-best equilibrium requires fixed prices.

costs are sufficiently high – i.e., if a second service does not improve customers' utilities –, the first-best allocation can be implemented.

<sup>&</sup>lt;sup>11</sup>Liu (2011) and Heinzel (2019a) study a credence goods market with selfish and conscientious experts. The authors show that the existence of conscientious experts in a market can lead to a more fraudulent behavior of the selfish type.

 $<sup>^{12}</sup>$ Heinzel (2019b) studies the impact of expert heterogeneity with respect to cost for treating a minor problem on the customers' search for second opinions.

<sup>&</sup>lt;sup>13</sup>Inderst and Ottaviani (2012a,b,c) and Inderst (2015) consider homogeneously imperfect diagnostic abilities in markets for financial advice. Balafoutas et al. (2020) analyze the interaction of homogeneously imperfect diagnostic abilities and insurance coverage.

Schneider and Bizer (2017b) experimentally test this model.<sup>14</sup> They find that experimental credence goods markets with expert moral hazard regarding the provision of truthful diagnoses are more efficient than predicted by theory. With regard to better expert qualification (in the sense of a larger share of high-ability experts), the authors find that market efficiency increases with fixed prices but remains unaffected or even declines with price competition.

Finally, Crettez et al. (2020) analyze the effectiveness of awareness campaigns to reduce overtreatment in a setting in which experts have different diagnostic abilities. Crucially, experts in their setting do not set prices, and respond to moral rather than direct monetary incentives of the different treatments. Moreover, low-ability experts do not get any information from the diagnosis in their setting.

The remainder of the paper is organized as follows. In the next section, we describe the model setup. In Section 3, we derive the equilibria, distinguishing between the cases of observable types (Section 3.1) and unobservable types (Section 3.2). In Section 4, we discuss the different equilibria in terms of efficiency and comparative statics and analyze extensions of our model: diagnosis effort, success verifiability, and competition. Section 5 concludes and provides some policy implications.

# 2 Model

Building on Dulleck and Kerschbamer (2009), we consider the following credence good market with a mass one of customers and a monopolistic expert. Each customer is aware that they have a problem, and that they need a major treatment with probability h or a minor treatment with probability 1-h. Each customer decides whether to visit an expert. When customers decide to do so, they are committed to undergoing the recommended treatment and paying the price charged for that treatment. Customers can observe the treatment performed and see whether the treatment is sufficient to heal the problem. Hence, customers can observe undertreatment but not overtreatment.<sup>15</sup> If the problem is healed, a customer receives a gross payoff equal to v. If it is not healed, a customer receives a gross payoff of zero. By assumption, a customer who is indifferent between visiting an expert and not visiting an expert decides in favor of a visit.

 $<sup>^{14}</sup>$ In a similar framework with ex-ante homogeneous experts, Momsen (2020) experimentally investigates how transparency influences outcomes in credence good markets.

<sup>&</sup>lt;sup>15</sup>However, we assume that undertreatment is not verifiable. We discuss this case in Section 4.5.

The expert can be one of two types, which is common knowledge. When the expert has high diagnostic ability, which happens with commonly known probability x, he performs an accurate diagnosis with certainty (at no cost), that is, he identifies the necessary treatment without making mistakes.<sup>16</sup> When the expert has low ability, which happens with probability 1 - x, he performs an accurate diagnosis with commonly known probability  $q \in [1/2, 1)$ .<sup>17</sup> Hence, a low-ability expert can make two types of errors, which occur both with probability 1-q: When the expert makes a false positive error, he diagnoses a major problem, although the customer only has a minor problem. Under a false negative error, the expert diagnoses a minor problem, but the customer has a major problem. The expert has costs of  $\bar{c}$  and  $\underline{c}$  for providing the major and minor treatment, respectively (with  $c < \bar{c}$ ). The major treatment heals any of the two problems, whereas the minor treatment only heals the minor problem. We assume that  $v > \bar{c}$  holds, which means that it is always (that is, even ex post) efficient to treat a customer. Furthermore, the expert sets prices  $\bar{p}$  and p for the major and minor treatment, respectively, and charges the customer for the recommended (verifiable) treatment. An expert's profit amounts to the price-cost margin per customer treated. When customers do not visit the expert, he makes zero profit. We assume that an expert cannot be held liable when providing an insufficient treatment.

The timing of events is as follows:

- 1. Nature determines whether the expert has high ability (with probability x) or low ability (with probability 1 x).
- 2. The expert learns his type and chooses a price vector  $\mathbf{P} = (\bar{p}, \underline{p})$ , which specifies a price for each of the two treatments.
- 3. Customers observe the prices, form beliefs  $\mu(\mathbf{P})$  that an expert setting a price vector  $\mathbf{P}$  is a high-ability expert, and decide whether to visit the expert. When customers do not visit the expert, the game ends, and both players receive payoffs of zero.
- 4. When customers visit the expert, nature determines whether they have a major problem (with probability h) or a minor problem (with probability 1-h).
- 5. When the expert has low ability, nature determines the outcome of the diagnosis, which is accurate with probability q. A low-ability expert type

 $<sup>^{16}</sup>$ Our results would not change qualitatively if the high-ability expert type also made mistakes (with a lower probability than the low-ability expert type).

<sup>&</sup>lt;sup>17</sup>Note that a probability lower than one half does not make sense, as in this case, the expert could provide better services by performing the treatment that was *not* diagnosed.

has beliefs  $\bar{\mu}$  ( $\underline{\mu}$ ) that a customer indeed faces the major (minor) problem when the diagnosis points to a major (minor) problem. A high-ability expert type always performs an accurate diagnosis.

6. The expert recommends and performs a treatment and charges the price for that treatment. Then, payoffs realize.

FIGURE 1 ABOUT HERE.

## 3 Analysis and results

We now derive the (non-trivial) equilibrium outcomes in the credence goods market specified above. We distinguish between two cases in which expert types are (i) observable and (ii) unobservable. We start by analyzing the benchmark case with observable types.

#### **3.1** Benchmark: Observable types

In order to analyze the optimal pricing and treatment decisions by the two expert types, we look at the relative price-cost margins for the two treatments.

#### 3.1.1 Price-cost margins

Three scenarios are possible: (i) The profit margin is larger for the major treatment; (ii) the profit margin is larger for the minor treatment; and (iii) the profit margins for the major and the minor treatment are the same. We focus on those equilibria that yield the highest profits in each (sub-)scenario.

In scenario (i), an expert – independent of his type (and, hence, observability) – finds it optimal to only recommend the major treatment, which implies that even for a high-ability expert type overtreatment occurs sometimes. Denote this case by superscript o, and note that a monopolistic expert always appropriates all surplus from trade, which means that optimal prices are given by

$$\bar{p}^{\circ} = v \tag{1}$$

and

$$\underline{p}^{\circ} \le v - \Delta c. \tag{2}$$

Here,  $\Delta c := \bar{c} - \underline{c}$  denotes the difference in treatment costs. The resulting profit amounts to

$$\pi^{\circ} = v - \bar{c}. \tag{3}$$

In scenario (ii), an expert – again independent of his type – finds it optimal to exclusively recommend the minor treatment to his customers. This means that even a high-ability expert type always chooses the minor treatment and this, sometimes undertreats his customers. In this case denoted by superscript u, optimal prices are given by

$$\bar{p}^{\mathrm{u}} \le (1-h)v + \Delta c \tag{4}$$

and

$$p^{u} = (1-h)v.$$
 (5)

The profit in this case amounts to

$$\pi^{\mathbf{u}} = (1-h)v - \underline{c}.\tag{6}$$

Given the observability of types, the pricing decision in scenario (iii), denoted by superscript e, depends on the expert's type because different abilities result in different expected gains from trade for customers.<sup>18</sup> Then, for a high-ability expert type (denoted by subscript H), the combination of the customers' binding participation constraint and equal markups leads to prices of

$$\bar{p}_H^{\rm e} = v + (1-h)\Delta c$$

and

$$\underline{p}_{H}^{\mathrm{e}} = v - h\Delta c.$$

The profit for this expert type equals

<sup>&</sup>lt;sup>18</sup>Scenario (iii) is a special case of the other two scenarios, but for the sake of brevity, we will not repeat the analyses of (i) and (ii) when analyzing (iii), although they also apply.

$$\pi_H^{\rm e} = v - \underline{c} - h\Delta c. \tag{7}$$

Similarly, the prices set by the low-ability expert type, denoted by subscript L, amount to

$$\bar{p}_L^{\rm e} = (1 - h + hq)v + (h - 2hq + q)\Delta c$$

and

$$\underline{p}_{L}^{e} = (1 - h + hq) v - (1 - h + 2hq - q) \Delta c$$

The profit for this type equals

$$\pi_L^{\rm e} = (1 - h + hq) \, v - \bar{c} + (h - 2hq + q) \, \Delta c. \tag{8}$$

Note that it holds that

$$\frac{\partial \pi_L^{\mathbf{e}}}{\partial q} = hv + (1 - 2h)\Delta c > 0, \tag{9}$$

which is due to the fact that  $v > \bar{c}$ . Not surprisingly, as customers' expected benefit from visiting an expert increases with the probability of receiving the accurate (sufficient) treatment, profits increase with better abilities.

Before characterizing the two types' optimal pricing behavior, let us briefly comment on efficiency. As the expert can fully extract the surplus, the expert is interested in maximizing customers' expected valuation. As a consequence, whenever an expert opts for a certain pricing scheme given observability of the type, this is also optimal from a social welfare point of view. As mentioned, profits under equal markups increase with better abilities, which means that the same is true for welfare.

Let  $\mathbf{P}^{\circ} := (\bar{p}^{\circ}, \underline{p}^{\circ}), \mathbf{P}^{u} := (\bar{p}^{u}, \underline{p}^{u})$ , and  $\mathbf{P}_{i}^{e} := (\bar{p}_{i}^{e}, \underline{p}_{i}^{e})$  (with  $i \in \{H, L\}$ ). We can now analyze the pricing and treatment decisions of the two types. We start with the high-ability expert type.

#### 3.1.2 High-ability expert type

The pricing behavior by the high-ability expert type, if the expert can commit to a strategy, has been studied before and can be characterized as follows: **Lemma 1** (Dulleck and Kerschbamer, 2006). An observable high-ability expert type efficiently serves all customers and sets a price vector  $\mathbf{P}_{H}^{e}$ .

*Proof.* Follows from a straightforward comparison of expression (7) and expressions (3) and (6), respectively, and the assumption that  $v > \bar{c}$ .

We can thus point out that the high-ability expert type benefits from offering equal-markup prices. By doing so, the expert can charge higher markups, as the expert credibly commits to treating customers honestly. At the same time, any problem is healed at the lowest cost, i.e., welfare is maximized.

#### 3.1.3 Low-ability expert type

In order to specify the optimal prices set by a low-ability expert, we note that

$$\pi^{\circ} \stackrel{<}{\underset{}{\leq}} \pi_{L}^{\circ} \Leftrightarrow h \stackrel{<}{\underset{}{\leq}} \frac{q\Delta c}{(1-q)v - (1-2q)\Delta c} =: h_{L}^{\circ}$$

and

$$\pi^{\mathbf{u}} \lneq \pi_{L}^{\mathbf{e}} \Leftrightarrow h \gtrless \frac{(1-q)\Delta c}{qv + (1-2q)\Delta c} =: h_{L}^{\mathbf{u}}.$$

Given these comparisons and definitions, we can state the following proposition:

**Proposition 1.** Given that a low-ability expert type makes diagnosis errors, an observable low-ability expert type efficiently serves his customers and sets the following prices:

$$\begin{cases} \mathbf{P}^{\mathrm{u}} & \text{if } h \in [0, h_{L}^{\mathrm{u}}], \\ \mathbf{P}_{L}^{\mathrm{e}} & \text{if } h \in (h_{L}^{\mathrm{u}}, h_{L}^{\mathrm{o}}], \\ \mathbf{P}^{\mathrm{o}} & else. \end{cases}$$

FIGURE 2 ABOUT HERE.

Figure 2 illustrates the pricing and treatment decisions by the low-ability expert type. As described, the expert's and the social planner's incentives are fully aligned. Hence, always choosing the major or the minor treatment can also be optimal from a welfare perspective. For example, when the probability of a major problem is not too low, and the probability of an accurate diagnosis is not too high, it is optimal to always recommend and perform the major treatment because the likelihood of failing to heal the customer's problem is greater than that of unnecessarily incurring the higher costs.

We now turn to the case with unobservable expert types.

#### 3.2 Unobservable types

In this part, we first present a general feature of the equilibrium outcomes in our setup. We then derive the equilibria and discuss two refinements.

#### 3.2.1 Preliminaries

With regard to equilibrium profits, we can state the following:

Lemma 2. In any equilibrium, both expert types make the same profit.

*Proof.* If one expert type made a strictly higher profit in an equilibrium by posting a certain price menu, the other type could easily mimic this offer and make the same strictly higher profit. As ability does not directly affect profits here, both types make the same profit as long as they charge the same prices.  $\Box$ 

Note that this implies that, given a costly opportunity to invest in their diagnostic ability, experts wouldn't have an incentive to do so unless this was observable.

There are equilibria in which different expert types post the same price vector as well as separating equilibria. In the price-pooling equilibria, different expert types achieve identical profits because their costs do not differ. For any separating equilibrium, there is a price-pooling equilibrium in which the expert provides the same treatment, and the customer pays the same price. The only difference between the two equilibria concerns the price for the treatment that is never chosen. Hence, we have:

**Corollary 1.** For any separating equilibrium, there is an outcome equivalent without separation in prices.

Thus, we focus on non-trivial pure-strategy perfect Bayesian Nash equilibria with price pooling. Among those, we focus on the ones which yield the highest profits.<sup>19</sup>

<sup>&</sup>lt;sup>19</sup>Additional equilibria exist in which both expert types provide the same treatments but post uniformly lower prices. Customers have off-equilibrium beliefs that any expert posting higher prices is a low-ability expert with sufficiently high probability. Hence, a customer would not visit the expert that posts higher prices.

#### 3.2.2 Definition and existence of equilibria with price pooling

Given the comparison of the two price-cost margins, there are three classes of equilibria: price pooling with (i) only major-treatment recommendations, with (ii) only minor-treatment recommendations, and with (iii) equal markups. The prices and profits for the first two scenarios are the same as in Subsection 3.1 (see expressions (1)-(6)).

In order to simplify the definition of the equilibria, we define the following values of the probability for a high-ability expert type:

$$\bar{x}^{\circ} := 1 - \frac{(1-h)\Delta c}{(1-q)(hv + (1-2h)\Delta c)}$$

and

$$\bar{x}^{\mathbf{u}} := \frac{-hqv + (1-q-h+2hq)\Delta c}{(1-q)(hv - (1-2h)\Delta c)}$$

We start by defining the first class of equilibria:

**Definition 1** (Major-treatment equilibria). *Major-treatment equilibria with* price pooling are characterized as follows:

- Both expert types choose the price vector  $\mathbf{P}^{\circ}$ .
- Both expert types always recommend and perform the major treatment.
- The low-ability expert type has beliefs  $\bar{\mu} = \mu = q$ .
- On the equilibrium path, customers' beliefs equal  $\mu(\mathbf{P}^{\circ}) = x$ , and customers always visit the expert.
- Off the equilibrium path, customers have beliefs:
  - $\mu \in [0, \bar{x}^{\circ}] \text{ if } \underline{p} \underline{c} = \overline{p} \overline{c} \text{ and } \overline{p} > \overline{p}^{\circ},$  $- \mu \in [0, 1] \text{ otherwise.}$

Next we define the second class of equilibria:

**Definition 2** (Minor-treatment equilibria). *Minor-treatment equilibria with* price pooling are characterized as follows:

• Both expert types choose the price vector  $\mathbf{P}^{u}$ .

- Both expert types always recommend and perform the minor treatment.
- The low-ability expert type has beliefs  $\bar{\mu} = \mu = q$ .
- On the equilibrium path, customers' beliefs equal  $\mu(\mathbf{P}^u) = x$ , and customers always visit the expert.
- Off the equilibrium path, customers have beliefs:
  - $\mu \in [0, \bar{x}^{u}] \text{ if } \underline{p} \underline{c} = \overline{p} \overline{c} \text{ and } \underline{p} > \underline{p}^{u},$
  - $\mu \in [0, 1]$  otherwise.

Let us briefly comment on the structure of these equilibria. In the majorrecommendation equilibria with price pooling, both types of experts choose their price vectors, such that they always optimally recommend the major treatment, independent of the customer's problem. Analogously, in the minorrecommendation equilibria with price pooling, both types choose their price vectors, such that it is always optimal to recommend the minor treatment. A low-ability expert type believes to have received the correct diagnosis with a probability that is equal to the accuracy of his diagnosis. Given that both expert types set identical prices, i.e., no information concerning expert types is conveyed, customers believe to face a certain expert type with the ex ante probability that this type is chosen by nature whenever the major-treatment (or minor-treatment, respectively) price vector is observed. With regard to customers' off-equilibrium beliefs, we distinguish two cases: First, when customers observe prices which are lower than those actually charged along the equilibrium path, there is no restriction with respect to the beliefs. This is due to the fact that both expert types do not have any incentive to set lower prices in the first place because this would only result in lower profits. Second, customers would be willing to pay a higher price to the high-ability type when they receive an appropriate treatment with a higher probability in return. This means that they must have a sufficiently weak belief that an expert setting higher prices than those to be charged along the equilibrium path indeed has high ability.

We now turn to equal-markup equilibria. In those, each type of expert may choose to either condition the treatment on the diagnosis or to always perform one of the two treatments. Thus, special cases of the major-treatment and minor-treatment equilibria can be equal-markup equilibria. When both types of experts follow the diagnosis, prices and profits for equal markups are given by

$$\bar{p}^{\rm e} = \left(1 - h + hq - hqx + hx\right)v + \left(h - 2hq + 2hqx - 2hx + q - qx + x\right)\Delta c$$

and

$$\underline{p}^{\mathbf{e}} = \left(1 - h + hq - hqx + hx\right)v - \left(1 - h + 2hq - 2hqx + 2hx - q + qx - x\right)\Delta c$$

Then, let  $\mathbf{P}^{e} := \left(\bar{p}^{e}, \underline{p}^{e}\right)$ . The profit for each type equals

$$\pi^{e} = (1 - h + hq - hqx + hx)v - \underline{c} - (1 - h + 2hq - 2hqx + 2hx - q + qx - x)\Delta c.$$
(10)

Again, both types make identical profits because ability does not play any role under equal-markup prices: Even when a low-ability expert type recommends the wrong treatment, the expert receives the same mark-up as the high-ability expert type.

A comparison of profits reveals that

$$\pi^{\circ} \lneq \pi^{\circ} \Leftrightarrow h \lneq \frac{(q - qx + x)\Delta c}{(1 - q + qx - x)v - (1 - 2q + 2qx - 2x)\Delta c} =: h^{\circ}$$

and

It holds that

$$\frac{\partial h^{\circ}}{\partial q}, \frac{\partial h^{\circ}}{\partial x} > 0, \tag{11}$$

and

$$\frac{\partial h^{\mathrm{u}}}{\partial q}, \frac{\partial h^{\mathrm{u}}}{\partial x} < 0.$$
(12)

Thus, both probabilities have a very similar effect on the two thresholds. This is due to the fact that the scenarios with only major-treatment/minortreatment recommendations are affected by neither of the two probabilities because the two expert types do not differ in their recommendations. Under equal mark-up pricing, social welfare is affected by diagnostic quality. However, because the expected gain from interaction is always zero for the customer, it does not make any difference for the customer whether the customer faces a high-ability expert with probability x (and consequently receives the accurate treatment with certainty), or whether the customer faces a low-ability expert type and receives the accurate treatment with probability q from an ex ante point of view.

More generally, let  $\mathbf{P}_{jk}^{e} := \left(\bar{p}_{jk}^{e}, \underline{p}_{jk}^{e}\right)$ , where  $j \in \{d, o, u\}$  specifies whether the high-ability expert type always follows his diagnosis or recommends the major or the minor treatment, where  $k \in \{d, o, u\}$  characterizes the respective recommendation decision for the low-ability expert type, and where

$$\bar{p}_{jk}^{e} = \underline{p}_{jk}^{e} + \Delta c = x \left[ \mathbb{1}_{j=o} v + \mathbb{1}_{j=u} ((1-h)v + \Delta c) + \mathbb{1}_{j=d} (v + (1-h)\Delta c) \right] + (1-x) \left[ \mathbb{1}_{k=o} v + \mathbb{1}_{k=u} ((1-h)v + \Delta c) + \mathbb{1}_{k=d} (v(1-h(1-q)) + ((1-h)q + h(1-q))\Delta c) \right].$$
(13)

The profits are  $\pi_{jk}^{e} = \bar{p}_{jk}^{e} - \bar{c}$ .

Given the above prices, we can define equal-markup equilibria:

**Definition 3** (Equal-markup equilibria). Equal-markup equilibria with price pooling are characterized as follows:

- Both expert types choose the price vector  $\mathbf{P}_{ik}^{e}$ .
- $j \in \{d, o, u\}$  specifies whether the high-ability expert type always follows his diagnosis or recommends and performs the major or the minor treatment, and  $k \in \{d, o, u\}$  does so for the low-ability expert type.
- The low-ability expert type has beliefs  $\bar{\mu} = \mu = q$ .
- On the equilibrium path, customers' beliefs equal  $\mu\left(\mathbf{P}_{jk}^{e}\right) = x$ , and customers always visit the expert.
- Off the equilibrium path, customers have beliefs:

$$\begin{aligned} &-\mu \in [0,\bar{x}] \text{ if } \underline{p} - \underline{c} = \overline{p} - \overline{c} \text{ and } \underline{p} > \underline{p}_{jk}^{e}, \\ &-\mu \in [0,1] \text{ otherwise.} \end{aligned}$$

Given identical markups, any treatment recommendation is equally profitable for an expert – independent of his type. As in the previously defined equilibria, a low-ability expert type believes to have received the correct diagnosis with a probability that equals the accuracy of his diagnosis. Again no information concerning expert types is revealed through the price setting, which means that customers believe they face a certain expert type with this type's (ex ante) probability to be selected by nature whenever the equal-markup price vector is posted by the expert. With regard to customers' off-equilibrium beliefs, prices which are higher than those to be charged along the equilibrium path must be accompanied by a sufficiently weak belief that the expert has high ability.<sup>20</sup> Again, there is no restriction with respect to the beliefs when customers observe prices which are lower than those charged along the equilibrium path.

Using these definitions, we can thus state equilibrium existence as follows:

**Proposition 2.** The existence of equilibria with price pooling is characterized as follows:

- (i) For  $h \in [0, h^{u}]$ , there exist minor-treatment equilibria;
- (ii) for  $h \in [h^{\circ}, 1]$ , there exist major-treatment equilibria;

(iii) for  $h \in [0, 1]$ , there exist equal-markup equilibria.

There exist several different types of equal-markup equilibria, some of which appear to be implausible. The usual equilibrium selection criteria do not have bite here because the expert's type does not affect his profits directly but only indirectly via equilibrium prices, which depend on customers' beliefs. In the following subsections, we further analyze equal-markup equilibria by imposing two assumptions on equilibrium selection that are relevant in different contexts.

#### 3.2.3 Refinements: Recommendation behavior

Having a closer look at the different recommendation options expert types have when they are indifferent due to equal-markup pricing, we first analyze the case in which experts follow their diagnosis. Then, we analyze the case in which experts maximize their customers' expected utility, which will also maximize equilibrium profits and overall efficiency.

#### Indifferent expert type follows his diagnosis

A scenario in which both expert types follow their diagnosis when they are indifferent may be relevant if experts are overconfident or completely unaware of

 $<sup>^{20}</sup>$ We constrain off-equilibrium beliefs in that case by assuming that customers believe that indifferent experts will not hurt them on purpose. More precisely, they believe that indifferent experts either follow their diagnosis or perform the ex-ante optimal treatment.

their type, or if they might want or need to justify their decision (for example, when presenting diagnosis outcomes in court).

We describe the set of equilibria in this case in the following proposition:

**Proposition 3.** The existence of equilibria with price pooling when indifferent experts follow their diagnosis is characterized as follows:

- (i) For  $h \in [0, h_L^u]$ , there exist minor-treatment equilibria;
- (ii) for  $h \in [h^u, h^o]$ , there exist equal-markup equilibria in which each expert type follows his diagnosis; and
- (iii) for  $h \in [h_L^{\circ}, 1]$ , there exist major-treatment equilibria.

Because  $h^u < h_L^u$  and  $h^o > h_L^o$ , there are multiple equilibria for some values of h but not for others.

Figure 3 illustrates the existence of the different equilibria. In all figures, the size of the gray areas (i.e., combinations of q and h) is determined by customers' off-equilibrium beliefs when observing higher (equal-markup) prices than those to be charged in the respective equilibria. The figures show the largest possible size of gray areas when higher-than-equilibrium equal-markup prices lead customers to believe that they face a low-ability expert type with certainty.

#### FIGURE 3 ABOUT HERE.

#### Indifferent expert type maximizes customers' expected utility

If both expert types maximize their customers' expected utility when they are indifferent, after setting the prices, experts behave as if their type were observable, i.e., the high-ability expert type will always follow his diagnosis, whereas the low-ability expert type will only do so if his diagnosis is correct with a sufficiently high probability. Otherwise, the low-ability expert type will always perform the major or the minor treatment, depending on which will lead to a higher expected utility for customers. The set of equilibria in this case is described in the following proposition:

**Proposition 4.** The existence of equilibria with price pooling when indifferent experts maximize customers' expected utility is characterized as follows:

(i) For  $h \in [0, h_L^u]$ , there exist minor-treatment equilibria;

- (ii) for  $h \in [h_L^{\circ}, 1]$ , there exist major-treatment equilibria;
- (iii) for  $h \in [0,1]$ , there exist equal-markup equilibria. In those, the highability expert type always follows his diagnosis. The low-ability expert type follows his diagnosis if  $h \in (h_L^u, h_L^o]$ , always performs the minor treatment if  $h \in [0, h_L^u]$ , and always performs the major treatment if  $h \in (h_L^o, 1]$ .

Figure 4 illustrates the existence of the different equilibria.

#### FIGURE 4 ABOUT HERE.

### 4 Discussion

In this section, we discuss the welfare properties of the equilibria considered and analyze how better diagnostic outcomes impact the relative efficiency of these equilibria. Moreover, we analyze how robust our results are to diagnosis effort, success verifiability, and competition.

#### 4.1 Welfare

We compare social welfare in the equilibria derived in the previous section, where social welfare is defined as the sum of (expected) expert and customer surplus. We consider an equilibrium to be efficient, if - given the diagnostic ability and the ex ante probability of customers having a major problem - there is no strategy that leads to a higher social welfare.

A first observation is that the minor-treatment and the major-treatment equilibria are never efficient because the high-ability type could always provide the correct diagnosis, which would result in cost savings. In contrast, the equal-markup equilibria in which the low-ability expert type maximizes his customers' utility are the efficient equilibria. For  $h \in (h_L^u, h_L^o]$ , these efficient equilibria coincide with the equal-markup equilibria in which both expert types follow their diagnosis. For all other parameter values, the equal-markup equilibria in which both expert types follow their diagnosis are inefficient. We can hence state the following result:

**Proposition 5.** Consider the equal-markup equilibria in which the high-ability expert type always follows his diagnosis, and the low-ability expert type follows his diagnosis if  $h \in (h_L^u, h_L^o]$ , performs the minor treatment if  $h \in [0, h_L^u]$ , and

performs the major treatment if  $h \in (h_L^{\circ}, 1]$ . These equilibria are efficient. The maximum prices are weakly higher than in any other equal-markup equilibrium with price pooling, and profits at those maximum prices are weakly higher than the profits in any other equilibrium.

From a policy perspective, it is an important question whether better diagnostic abilities improve the market outcome – in particular when such an endeavor involves substantial costs. Such an improvement can come in two forms: First, the low-ability expert type may become better at supplying an accurate diagnosis (i.e., q increases). Second, the probability that an expert is a high type increases (i.e., x increases). We next discuss each improvement separately. In order to compare equilibrium outcomes, we define the relative efficiency as the share of surplus relative to the surplus under the efficient equilibrium.

#### 4.2 Increase in diagnostic precision

The effect of an increase in the diagnostic precision crucially depends on the ex ante probability of customers having a major problem as well as the equilibrium played. We first outline the impact of an increase in diagnostic precision on social welfare under the efficient equilibria. Then, we compare how relative social welfare in the other equilibria is affected by an increase in diagnostic precision.

For the efficient equilibria and a high ex ante probability of customers having a major problem  $(h \in (h_L^{\circ}, 1])$ , the low-ability expert always provides the major treatment. Hence, a marginal increase in the diagnostic precision does not change the surplus. This also holds for a low likelihood that customers suffer from a major problem  $(h \in [0, h_L^u])$ , where the low-ability expert always undertreats independent of his diagnostic signal. In contrast, whenever customers have the major problem with some intermediate probability  $(h \in (h_L^u, h_L^o])$ , both expert types follow their diagnostic signal. Then, a more precise diagnosis leads to a higher surplus because the low-ability expert provides the appropriate treatment for customers more often.

Next, we investigate the impact of a higher precision of diagnostic ability in the other equilibria on social welfare relative to the above benchmark. We differentiate three cases based on the ex ante probability that a customer suffers from a major problem h: high  $(h > (1 + x)\Delta c/((1 - x)v + 2x\Delta c)))$ , medium  $(h \in (\Delta c/v, (1 + x)\Delta c/((1 - x)v + 2x\Delta c)))$ , and low probability  $(h < (1 + x)\Delta c/((1 - x)v + 2x\Delta c)))$ .

#### FIGURE 5 ABOUT HERE.

For the case of a high probability for the major problem, (inefficient) majortreatment equilibria exist besides the efficient equilibria for low values of q. *Figure 5* illustrates this case. For low values of q, it is efficient that a lowability expert always provides the major treatment. Hence, an increase in diagnostic precision neither changes the behavior of experts in a major-treatment equilibrium nor in an efficient equilibrium. The relative efficiency of the majortreatment equilibrium does not change. For medium values of q, equal-markup equilibria exist in which both expert types follow their diagnosis. The relative efficiency of these equilibria increases with an increase in diagnostic precision, as the low-ability type's diagnosis becomes more accurate. If customers and the expert coordinate on the major-treatment equilibrium, the increase in diagnostic precision again does not change relative efficiency. For high values of q, only the two equal-markup equilibria exist and coincide. Hence, an increase in diagnostic precision does not change relative efficiency.

In the case with a medium probability for the major problem, the majortreatment equilibria and the equal mark-up equilibria in which experts follow their diagnosis when they are indifferent exist also for low values of q. Figure 6 displays this case. Starting from a low value of q, an increase in the diagnostic precision leads to a lower relative inefficiency in the equal-markup equilibria in which experts follow their diagnosis. This does not hold for the major-treatment equilibria. There, the relative inefficiency persists. When qis sufficiently high, both equal-markup equilibria coincide.

#### FIGURE 6 ABOUT HERE.

The case of a low probability for the major problem is analogous to the case of a high probability. We can thus summarize our findings in the following proposition:

**Proposition 6.** When both types do not choose an equal-markup price vector for  $h \in (h^{u}, h^{u}_{L})$  or  $h \in (h^{o}_{L}, h^{o})$ , better diagnostic abilities of the low-ability expert type do not decrease relative inefficiencies.

#### 4.3 Increase in probability of high-ability expert

The second dimension that might be important for a policy-maker is the share of high-ability experts in the market. This section analyzes how such a higher share affects relative efficiency in the market.

#### FIGURE 7 ABOUT HERE.

Figure 7 illustrates the existence of the different equilibria depending on the diagnostic precision and the probability for a high-ability expert type. A first observation is that for relatively precise diagnoses  $(q > (v - \Delta c)h/(hv + (1 - 2h)\Delta c))$ , only equal-markup equilibria exist. The two equal-markup equilibria coincide. For a lower diagnostic precision  $(q \le (v - \Delta c)h)/(hv + (1 - 2h)\Delta c))$ , multiple equilibria that actually lead to different behaviors exist: For lower values of q and high values of x, the major-treatment equilibria and the two types of equal-markup equilibria exist. For lower values of q and x, only the major-treatment equilibria exist.

With regard to the impact of an increase in the probability for a high-ability expert, there is no change in relative efficiency for high values of q  $(q > (v - \Delta c)h)/(hv + (1-2h)\Delta c))$ , where only equal-markup equilibria exist. For lower values of q  $(q \le (v - \Delta c)h/(hv + (1-2h)\Delta c))$  and low values of x, an increase in the probability for a high-ability expert type leads to an increase in the surplus under the efficient equilibrium. In the major-treatment equilibria, high-ability experts stick to providing a major treatment, although they could provide the appropriate treatment. Hence, the relative efficiency of major-treatment equilibria increases. For higher values of x, the equilibria in which experts follow their diagnosis also exist.

An increase in x leads to a lower relative inefficiency, as the probability for an incorrect diagnosis by low-ability experts decreases. *Figure 8* illustrates the case for lower values of q.

Note that neither increasing x nor q actually decreases absolute efficiency if there is no direct cost of doing so. However, if increasing those is not free, a policy maker should not make use of this option if players coordinate on the major- or the minor-treatment equilibria, unless in combination with other policies that have the potential to get rid of those equilibria, such as price regulation or increasing transparency. A further important exception is the following: As *Figure 7* illustrates, if the policy maker increases q not only marginally but by sufficiently much, those equilibria do not exist anymore. Increasing x to a value smaller than one does not have such an effect.

#### FIGURE 8 ABOUT HERE.

#### 4.4 Effort

In our basic model, we have assumed that diagnostic ability is exogenous. However, our results extend to several important situations in which the expert can exert effort to influence the diagnosis precision. First, if effort is not observable or too costly, the expert does not have an incentive to exert any effort. Our exogenous diagnostic ability could be interpreted as the exogenous baseline diagnostic ability (for exerting no effort) in this case.<sup>21</sup> Second, if effort is verifiable, but both types face the same effort costs, they choose the same effort, because they make the same profit.<sup>22</sup> Moreover, this is also the case if the costs are not the same but similar enough, such that the low-ability type wants to imitate the high-ability type. In either case, our exogenously given diagnostic abilities could be interpreted as endogenous total diagnostic abilities, no matter whether the heterogeneity stems from different baseline diagnostic abilities, different translations of effort into diagnosis improvements, or a combination of the two. This reasoning also applies, of course, if the different expert types choose different effort levels in equilibrium (e.g., because they do not have the same effort levels to choose from), but those different levels cannot be told apart.

#### 4.5 Fines and warranties

Throughout the paper, we have assumed that the success or failure of the treatment are not verifiable. Now we assume that the treatment outcome is verifiable, and that the expert has to pay a fine f > 0 whenever the treatment is insufficient. A compensation that the expert has to pay to the customer in case the treatment is insufficient (warranty) would work in the same way.<sup>23</sup>

Introducing a fine implies that the major-treatment equilibria no longer exist: Because the high-ability expert knows better when she can recommend a minor treatment without risking a fine, there exists a price vector, such that the highability expert has a strict incentive to recommend the appropriate treatment, and the low-ability expert has a strict incentive to always recommend the major treatment in order to avoid the potential fine (such a price vector would have a slightly smaller profit margin for the major treatment when not taking into account the fine). Because this is the efficient thing to do for a low-ability expert in that parameter region, customers' willingness to pay would increase, resulting in a higher profit margin for both treatments, and, hence, giving the high-ability expert the opportunity to profitably deviate.

<sup>&</sup>lt;sup>21</sup>Recall that our results do not depend on the high-ability type having perfect ability.

 $<sup>^{22}</sup>$ Our results for unobservable types apply as long as experts do not end up with the same diagnostic ability. If they end up with the same diagnostic ability, we are essentially back to a situation in which types are observable, and our results of Section 3.1 apply.

<sup>&</sup>lt;sup>23</sup>Note that fines and compensations are similar to what the literature calls liability. However, in contrast to liability, the expert may (and, depending on parameters, sometimes will) provide an insufficient treatment.

Moreover, introducing a fine implies that the minor-treatment equilibria no longer exist: Because the high-ability expert knows better when she has to recommend a major treatment and should not risk the fine, there exists a price vector, such that the high-ability expert has a strict incentive to recommend the appropriate treatment, and the low-ability expert has a strict incentive to always recommend the minor treatment (if the fine is not large), while risking the fine (such a price vector would have a slightly smaller profit margin for the major treatment when not taking into account the fine, even slightly smaller than in the deviation price vector in the above paragraph). Because this is the efficient thing to do for a low-ability expert in that parameter region, customers' willingness to pay would increase, resulting in a higher profit margin for both treatments, and, hence, giving the high-ability expert the opportunity to profitably deviate.

Note also that for all of the efficient equal-markup equilibria that we derived for the case in which success is not verifiable, there exist equilibria in which the expert employs the same treatment strategy, and customers always visit for the case in which success is verifiable. In contrast, the inefficient equalmarkup equilibria are not robust, because there is always a profitable deviation price vector that unambiguously determines either expert type's treatment strategy. Thus, (even small) fines and warranties are adequate policy tools for implementing efficient market outcomes if the treatment success is verifiable.

#### 4.6 Competition

So far, we have assumed that the expert is a monopolist. This subsection demonstrates that our results are robust to competition. The surplus shifts from experts to customers, but the equilibrium treatment strategies continue to exist, and, hence, efficiency remains unchanged. In the following, we consider a situation in which at least two experts compete à la Bertrand.

When the experts' types are observable, we have to consider three different cases. First, if there are at least two experts with a high diagnostic ability, at least two high-ability experts charge prices as in Section 3.1, the only difference being that the prices of both treatments are reduced by their expected profit as given in Section 3.1. Customers only visit those experts, and those experts follow their diagnosis. Other experts charge prices that are not attractive for customers. Thus, all experts make zero profits, and no one has an incentive to deviate. Second, if all experts have a low ability, at least two of them charge prices as in Section 3.1, the only difference being that the prices of both treatments are reduced by their expected profit as given in Section 3.1. Customers only visit those experts, and those experts employ the treatment strategy of Section 3.1. Other experts charge prices that are not attractive for customers. Again, all experts make zero profits, and no one has an incentive to deviate. Third, if there is exactly one expert with a high ability, at least one low-ability expert charges prices as in Section 3.1, the only difference being that the prices of both treatments are reduced by the low-ability type's expected profit given in Section 3.1. The high-ability expert reduces her prices from Section 3.1 by the same amount, such that customers are indifferent between visiting her and the low-ability expert. However, in equilibrium, all customers visit the high-ability expert who follows her diagnosis. All other experts charge prices that are not attractive for customers. Thus, all low-ability experts make zero profits, and no one has an incentive to deviate. The high-ability expert makes positive profits, but does not have an incentive to deviate either.

We can thus summarize experts' treatment decisions for the case with observable types as follows:

**Proposition 7.** Given any parameter values, if an expert's treatment strategy is part of an equilibrium in the monopoly case, it is also part of an equilibrium in the competition case.

When the experts' types are not observable, low-ability experts can - as in the monopoly case – imitate a high-ability expert at no cost, because they have the same profit function.<sup>24</sup> Thus, all equilibria derived in Section 3.2 have a treatment-equivalent equilibrium with the corresponding prices from Section 3.2, the only difference being that the prices of both treatments are reduced by experts' expected profit in the corresponding equilibrium as given in Section 3.1. At least two experts charge those prices, customers only visit those experts, and other experts charge unattractive prices. Experts make zero profits, and no one has an incentive to deviate. However, if q is large and h is intermediate, there are additional equal-markup equilibria in which experts make positive profits, as long as they charge only moderate prices: If there is no profitable major-treatment or minor-treatment vector that would also appeal to customers, customers may also hold the belief that a deviating expert posting an equal-markup price vector provides a diagnosis-independent treatment, which is not attractive to customers. If prices were too high, an expert could deviate by posting a major- and minor-treatment price vector. This means that the threat of major- and minor-treatment price vectors can provide commitment against high prices.

We can summarize our analysis of competition with unobservable types analogously to Proposition  $2:^{25}$ 

 $<sup>^{24}\</sup>mathrm{Hence},$  it also does not matter whether experts can observe each others' types.

<sup>&</sup>lt;sup>25</sup>The results of Propositions 3 and 4 extend analogously.

**Proposition 8.** In the case of Bertrand competition with at least two experts, the existence of equilibria with price pooling is characterized as follows:

- (i) for  $h \in [0, h^u]$ , there exist equilibria with minor-treatment price vectors;
- (ii) for  $h \in [h^{\circ}, 1]$ , there exist equilibria with major-treatment price vectors;
- (iii) for  $h \in [0,1]$ , there exist equilibria with equal-markup price vectors.

Thus, because the treatments under competition are the same as with a monopolistic expert, the efficiency concerns remain unchanged.

# 5 Conclusion

We present a credence goods model with expert types that differ in their diagnostic ability. Whereas a high-ability expert type always performs a correct diagnosis with regard to the customer's problem, a low-ability expert type does not always deliver an accurate diagnosis. Thus, a low-ability expert type sometimes makes mistakes when diagnosing customers.

In our benchmark case with observable expert types, both expert types post equal-markup prices to signal that they have no incentive to overtreat or undertreat. The high-ability expert posts higher prices than the low-ability type, because the customers' valuation for receiving a correct diagnosis (and treatment) is higher than for a possibly incorrect one. Furthermore, profits are higher for the high-ability type than for the low-ability type.

Under unobservable expert types, we find that efficient market outcomes always exist. Nevertheless, expert types may also coordinate on inefficient equilibria. In both – efficient and inefficient – equilibria, the two expert types post equal prices. This is the case, because the low-ability expert type could always mimic the high-ability expert type when the latter deviates from equal prices. Hence, markups and profits are identical for both expert types, which also implies that there are not any private benefits to improving one's diagnostic ability. Increasing transparency, that is, making expert types observable, would weakly increase social welfare in our set-up.

Relative to the social welfare under efficient equilibria, a marginal increase in the low-ability type's diagnostic ability does not necessarily improve social welfare. Welfare depends on the probability that customers need a major treatment and on the equilibrium experts coordinate on. We find that relative social welfare does not improve if the probability for a major problem is sufficiently high or sufficiently low. Only for an intermediate likelihood, an increase in relative social welfare results if the expert types post equal-markup prices and follow their own diagnosis.

We observe that an increase in the share of the high-ability type can even decrease relative social welfare. If expert types coordinate on an equilibrium in which both expert types always provide the major treatment, increasing the probability for a high-ability expert does not change the behavior of expert types, although the high-ability expert type would be able to provide a correct diagnosis.

A sufficiently large increase in the low-ability type's diagnostic ability can guarantee an efficient equilibrium, increasing the share of high-ability experts would only do so if there was no low-ability type left at all. This implies that increasing minimum standards for experts can be a more successful policy than increasing the share of excellent experts.

If the success or failure of a treatment is verifiable, warranties or fines for an insufficient treatment seem useful policy tools. Without such verifiability, the optimal policy is not as straightforward.

Our results suggest that a regulation that obliges experts to follow the diagnostic results can be detrimental to relative social welfare. Such a regulation supports the efficient equilibrium only if diagnostic precision is sufficiently high. Moreover, it is never optimal to require both expert types to always provide a certain treatment. However, if the policy maker can differentiate expert types, requiring the low-type to always provide a certain treatment is optimal if the low-ability type's ability is sufficiently low. Overall, our results show that a careful design of expert markets is necessary to attain the social optimum.

# References

- Alger, I. and F. Salanié (2006). A Theory of Fraud and Overtreatment in Experts Markets. Journal of Economics & Management Strategy 15, 853– 881.
- Balafoutas, L., A. Beck, R. Kerschbamer, and M. Sutter (2013). What drives taxi drivers? A field experiment on fraud in a market for credence goods. *Review of Economic Studies 80*, 876–891.
- Balafoutas, L., H. Fornwagner, R. Kerschbamer, M. Sutter, and M. Tverdostup (2020). Diagnostic uncertainty and insurance in credence goods markets. University of Innsbruck Working Papers in Economics and Statistics 2020-21.
- Balafoutas, L., R. Kerschbamer, and M. Sutter (2017). Second-degree moral hazard in a real-world credence goods market. *Economic Journal 127*, 1–18.
- Bester, H. and M. Dahm (2017). Credence goods, costly diagnosis and subjective evaluation. *Economic Journal 128*, 1367–1394.
- Brammer, R. (2002). Effects of experience and training on diagnostic accuracy. Psychological Assessment 14, 110–113.
- Brush, J. E., J. Sherbino, and G. R. Norman (2017). How expert clinicians intuitively recognize a medical diagnosis. *American Journal of Medicine 130*, 629–634.
- Chan, D., M. Gentzkow, and C. Yu (2019). Selection with variation in diagnostic skill: Evidence from radiologists. Working Paper, NBER, No. 26467.
- Coderre, S., D. Jenkins, and K. Mclaughlin (2009). Qualitative differences in knowledge structure are associated with diagnostic performance in medical students. Advances in Health Sciences Education 14, 677–684.
- Crettez, B., R. Deloche, and M.-H. Jeanneret-Crettez (2020). A demandinduced overtreatment model with heterogeneous experts. *Journal of Public Economic Theory*, forthcoming.
- Darby, M. R. and E. Karni (1973). Free competition and the optimal amount of fraud. *Journal of Law and Economics* 16, 67–88.
- Dulleck, U. and R. Kerschbamer (2006). On doctors, mechanics, and computer specialists: The economics of credence goods. *Journal of Economic Literature* 44, 5–42.

- Dulleck, U. and R. Kerschbamer (2009). Experts vs. discounters: Consumer free-riding and experts withholding advice in markets for credence goods. *International Journal of Industrial Organization* 27, 15–23.
- Dulleck, U., R. Kerschbamer, and M. Sutter (2011). The economics of credence goods: An experiment on the role of lability, verifiability, reputation, and competition. *American Economic Review 101*, 526–555.
- ECDC Technical Report (2019). Survey of healthcare workers' knowledge, attitudes and behaviours on antibiotics, antibiotic use and antibiotic resistance in the EU/EEA.
- Emons, W. (1997). Credence goods and fraudulent experts. RAND Journal of Economics 28, 107–119.
- Emons, W. (2001). Credence goods monopolists. International Journal of Industrial Organization 19, 375–389.
- Federal Bureau of Investigation (2011). Financial crimes report to the public: Fiscal year 2010–2011. United States Department of Justice.
- Fong, Y.-f. (2005). When do experts cheat and whom do they target? *RAND Journal of Economics 36*, 113–130.
- Frankel, A. and M. Schwarz (2014). Experts and their records. *Economic Inquiry* 52, 56–71.
- Gottschalk, F., W. Mimra, and C. Waibel (2018). Health services as credence goods: A field experiment. *Working Paper, SSRN, No. 3036573*.
- Heinzel, J. (2019a). Credence goods markets with fair and opportunistic experts. Working Paper, Center for International Economics, No. 2019-02.
- Heinzel, J. (2019b). Credence goods markets with heterogeneous experts. Working Paper, Center for International Economics, No. 2019-01.
- Hilger, N. G. (2016). Why don't people trust experts? Journal of Law and Economics 59, 293–311.
- Hyndman, K. and S. Ozerturk (2011). Consumer information in a market for expert services. *Journal of Economic Behavior & Organization 80*, 628–640.
- Inderst, R. (2015). Regulating commissions in markets with advice. International Journal of Industrial Organization 43, 137–141.

- Inderst, R. and M. Ottaviani (2012a). Competition through commissions and kickbacks. American Economic Review 102, 780–809.
- Inderst, R. and M. Ottaviani (2012b). Financial advice. Journal of Economic Literature 50, 494–512.
- Inderst, R. and M. Ottaviani (2012c). How (not) to pay for advice: A framework for consumer financial protection. *Journal of Financial Economics* 105, 393–411.
- Jost, P.-J., S. Reik, and A. Ressi (2019). The information paradox in a monopolist's credence goods market. *Working Paper*.
- Kerschbamer, R., D. Neururer, and M. Sutter (2016). Insurance coverage of customers induces dishonesty of sellers in markets for credence goods. *Proceedings of the National Academy of Science* 113, 7454–7458.
- Kerschbamer, R. and M. Sutter (2017). The economics of credence goods—a survey of recent lab and field experiments. CESifo Economic Studies 63, 1–23.
- Kerschbamer, R., M. Sutter, and U. Dulleck (2017). How social preferences shape incentives in (experimental) markets for credence goods. *Economic Journal 127*, 393–416.
- Lambert, L. E. and M. Wertheimer (1988). Is diagnostic ability related to relevant training and experience? Professional Psychology: Research and Practice 19, 50–52.
- Liu, T. (2011). Credence goods markets with conscientious and selfish experts. International Economic Review 52, 227–244.
- McGuire, T. G. (2000). Physician agency. In A. J. Culyer and J. P. Newhouse (Eds.), *Handbook of Health Economics*, Volume 1, Part A, pp. 461–536. Elsevier.
- Mimra, W., A. Rasch, and C. Waibel (2016a). Price competition and reputation in credence goods markets: Experimental evidence. *Games and Economic Behavior 100*, 337–352.
- Mimra, W., A. Rasch, and C. Waibel (2016b). Second opinions in markets for expert services: Experimental evidence. Journal of Economic Behavior & Organization 131, 106–125.
- Momsen, K. (2020). Recommendations in credence goods markets with horizontal product differentiation. *Unpublished*.

- Obradovits, M. and P. Plaickner (2020). Searching for treatment. University of Innsbruck Working Papers in Economics and Statistics 2020-18.
- Pesendorfer, W. and A. Wolinsky (2003). Second opinions and price competition: Inefficiency in the market for expert advice. *Review of Economic Studies 70*, 417–437.
- Rasch, A. and C. Waibel (2018). What drives fraud in a credence goods market? Evidence from a field study. Oxford Bulletin of Economics and Statistics 80, 605–624.
- Schneider, H. S. (2012). Agency problems and reputation in expert services: Evidence from auto repair. *Journal of Industrial Economics* 60, 406–433.
- Schneider, T. and K. Bizer (2017a). Effects of qualification in expert markets with price competition and endogenous verifiability. Working Paper, Center for European, Governance and Economic Development Research, No. 317.
- Schneider, T. and K. Bizer (2017b). Expert qualification in markets for expert services: A Sisyphean task? Discussion Papers, Center for European, Governance and Economic Development Research, No. 323.
- Taylor, C. R. (1995). The economics of breakdowns, checkups, and cures. Journal of Political Economy 103, 53–74.
- Xue, H., Y. Shi, L. Huang, H. Yi, H. Zhou, C. Zhou, S. Kotb, J. D. Tucker, and S. Y. Sylvia (2019). Diagnostic ability and inappropriate antibiotic prescriptions: a quasi-experimental study of primary care providers in rural China. Journal of Antimicrobial Chemotherapy 74, 256–263.

# 6 Figures



Figure 1: Timing of events in the expert market.

Notes: We refrain from explicitly stating the treatment choice in the game tree because due to verifiability, the expert's price choice implies the respective treatment. Note further that the first (second) entry in the payoff vector represents customer (expert) payoff.



Figure 2: Pricing of an observable low-ability expert type.



Figure 3: Equilibrium pricing when an indifferent expert type follows his diagnosis.



Figure 4: Equilibrium pricing when an indifferent expert type maximizes his customers' expected utility.



Figure 5: Market (in)efficiency when a major problem occurs with sufficiently high probability  $(h > (1+x)\Delta c/((1-x)v + 2x\Delta c))$ , and when off-equilibrium beliefs equal zero.



Figure 6: Market (in)efficiency when a major problem occurs with medium probability  $(h \in (\Delta c/v, (1+x)\Delta c/((1-x)v+2x\Delta c)))$ , and when off-equilibrium beliefs equal zero.



Figure 7: Equilibrium pricing for combinations of q and x (for  $h > \Delta c/v$ ).



Figure 8: Market (in)efficiency when major problem occurs with sufficiently high probability  $(h > \Delta c/v)$ , when diagnostic quality of the low-ability expert type is sufficiently low  $(q < (v - \Delta c)h/(hv + (1 - 2h)\Delta c))$ , and when off-equilibrium beliefs equal zero.

Note: The gray area demonstrates the maximum size of customers' off-equilibrium beliefs when observing higher prices than those to be charged in the respective equilibria.